BCM
TEVA icon

Boreal Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Boreal Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.13K Hold
122
– – ﹤0.01% 419
2026
Q1 		$3.67K Hold
122
– – ﹤0.01% 420
2025
Q4 		$3.81K Sell
122
-200
-62% -$4.93K ﹤0.01% 440
2025
Q3 		$6.5K Sell
322
-100
-24% -$1.76K 0.01% 415
2025
Q2 		$7.07K Buy
+422
New +$6.81K 0.01% 378

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Boreal Capital Management's TEVA Position: Q2 2026 in Review

Boreal Capital Management held its Teva Pharmaceuticals (TEVA) position steady in Q2 2026 at 122 shares worth $4.13K. The position accounts for ﹤0.01% of the portfolio, ranked #419.

Boreal Capital Management first reported a position in TEVA in Q2 2025 and has held it in 5 quarters since. The position peaked at $7.07K in Q2 2025. 673 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Boreal Capital Management held 122 shares of Teva Pharmaceuticals worth $4.13K as of Q2 2026.
  • Boreal Capital Management left its Teva Pharmaceuticals share count unchanged in Q2 2026.
  • Teva Pharmaceuticals made up ﹤0.01% of Boreal Capital Management's portfolio in Q2 2026, its #419 holding.
  • Boreal Capital Management first reported a position in Teva Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • Boreal Capital Management's Teva Pharmaceuticals position peaked at $7.07K in Q2 2025.
  • 673 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Boreal Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.